Trial Profile
Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Eribulin (Primary) ; Stenoparib (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- 24 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 30 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 27 Mar 2015 New trial record